Role of free fatty acid receptor 2 (FFAR2) in the regulation of metabolic homeostasis

Current Drug Targets

Volumn 16, Issue 7, 2015, Pages 771-775

  Mohammad, Sameer ^a  

^a KING SAUD BIN ABDULAZIZ UNIVERSITY FOR HEALTH SCIENCES   (Saudi Arabia)

Author keywords

Free fatty acid receptors; Gut microbiota; Insulin resistance; Metabolic homeostasis; Short chain fatty acids; Type 2 diabetes

Indexed keywords

FREE FATTY ACID RECEPTOR 2; G PROTEIN COUPLED RECEPTOR; GLUCAGON LIKE PEPTIDE 1; ISOPRENALINE; SHORT CHAIN FATTY ACID; UNCLASSIFIED DRUG; CELL SURFACE RECEPTOR; G-PROTEIN COUPLED RECEPTOR 43, HUMAN;

ADIPOGENESIS; ADIPOSE TISSUE; ARTICLE; CELL DIFFERENTIATION; GENE EXPRESSION; GLUCOSE TOLERANCE; HOMEOSTASIS; HUMAN; IMMUNOREGULATION; INSULIN SENSITIVITY; LIPOLYSIS; METABOLIC DISORDER; METABOLIC REGULATION; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBESITY; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; ANIMAL; ENERGY METABOLISM; INSULIN RESISTANCE; METABOLISM; PHYSIOLOGY;

ADIPOSE TISSUE; ANIMALS; ENERGY METABOLISM; HOMEOSTASIS; HUMANS; INSULIN RESISTANCE; RECEPTORS, CELL SURFACE;

EID: 84939800174     PISSN: 13894501     EISSN: 18735592     Source Type: Journal    
DOI: 10.2174/1389450116666150408103557     Document Type: Article

References (48)

1. Hirasawa A, Hara T, Katsuma S, Adachi T, Tsujimoto G. Free fatty acid receptors and drug discovery. Biol Pharm Bull 2008; 31(10): 1847-51.
2. Ichimura A, Hirasawa A, Hara T, Tsujimoto G. Free fatty acid receptors act as nutrient sensors to regulate energy homeostasis. Prostaglandins Other Lipid Mediat 2009; 89(3-4): 82-8.
3. Rayasam GV, Tulasi VK, Davis JA, Bansal VS. Fatty acid receptors as new therapeutic targets for diabetes. Expert Opin Ther Targets 2007; 11(5): 661-71.
4. Rutter GA. Insulin secretion: fatty acid signalling via serpentine receptors. Curr Biol 2003; 13(10): R403-5.
5. Hirasawa A, Tsumaya K, Awaji T, et al. Free fatty acids regulate gut incretin glucagon-like peptide-1 secretion through GPR120. Nat Med 2005; 11(1): 90-4.
6. Salehi A, Flodgren E, Nilsson NE, et al. Free fatty acid receptor 1 (FFA(1)R/GPR40) and its involvement in fatty-acid-stimulated insulin secretion. Cell Tissue Res 2005 322(2): 207-15.
7. Kaemmerer E, Plum P, Klaus C, et al. Fatty acid binding receptors in intestinal physiology and pathophysiology. World J Gastrointest Pathophysiol 2010; 1(5): 147-53.
8. Morgan NG, Dhayal S. G-protein coupled receptors mediating long chain fatty acid signalling in the pancreatic beta-cell. Biochem Pharmacol 2009; 78(12): 1419-27.
9. Brown AJ, Jupe S, Briscoe CP. A family of fatty acid binding receptors. DNA Cell Biol 2005; 24(1): 54-61.
10. Macfarlane GT, Macfarlane S. Bacteria, colonic fermentation, and gastrointestinal health. J AOAC Int 2012; 95(1): 50-60.
11. Lin HV, Frassetto A, Kowalik EJ Jr, et al. Butyrate and propionate protect against diet-induced obesity and regulate gut hormones via free fatty acid receptor 3-independent mechanisms. PLoS One 2012; 7(4): e35240.
12. Galvez J, Rodriguez-Cabezas ME, Zarzuelo A. Effects of dietary fiber on inflammatory bowel disease. Mol Nutr Food Res 2005; 49(6): 601-8.
13. Sanderson IR. Short chain fatty acid regulation of signaling genes expressed by the intestinal epithelium. J Nutr 2004; 134(9): 2450S- 2454S.
14. D'Argenio G, Mazzacca G. Short-chain fatty acid in the human colon. Relation to inflammatory bowel diseases and colon cancer. Adv Exp Med Biol 1999; 472: 149-58.
15. Brown AJ, Goldsworthy SM, Barnes AA, et al. The Orphan G protein-coupled receptors GPR41 and GPR43 are activated by propionate and other short chain carboxylic acids. J Biol Chem 2003; 278(13): 11312-9.
16. Le Poul E, Loison C, Struyf S, et al. Functional characterization of human receptors for short chain fatty acids and their role in polymorphonuclear cell activation. J Biol Chem 2003; 278(28): 25481-9.
17. Nilsson NE, Kotarsky K, Owman C, Olde B. Identification of a free fatty acid receptor, FFA2R, expressed on leukocytes and activated by short-chain fatty acids. Biochem Biophys Res Commun 2003; 303(4): 1047-52.
18. Tiwari A. GPR43: an emerging target for the potential treatment of type 2 diabetes, obesity and insulin resistance. Curr Opin Investig Drugs 2010; 11(4): 385-93.
19. Kimura I, Inoue D, Hirano K, Tsujimoto G. The SCFA receptor GPR43 and energy metabolism. front endocrinol (Lausanne) 2014. 5: 85.
20. Kim S, Kim YM, Kwak YS. A novel therapeutic target, GPR43; where it stands in drug discovery. Arch Pharm Res 2012; 35(9): 1505-9.
21. Bindels LB, Dewulf EM, Delzenne NM. GPR43/FFA2: physiopathological relevance and therapeutic prospects. Trends Pharmacol Sci 2013; 34(4): 226-32.
22. Harwood HJ Jr. The adipocyte as an endocrine organ in the regulation of metabolic homeostasis. Neuropharmacology 2012; 63(1): 57-75.
23. Ge H, Li X, Weiszmann J, et al. Activation of G protein-coupled receptor 43 in adipocytes leads to inhibition of lipolysis and suppression of plasma free fatty acids. Endocrinology 2008; 149(9): 4519-26.
24. Hong YH, Nishimura Y, Hishikawa D, et al. Acetate and propionate short chain fatty acids stimulate adipogenesis via GPCR43. Endocrinology 2005; 146(12): 5092-9.
25. Hou Z, Sun C. Transcriptional expression of GPR43 gene in adipose tissue and primary cultured adipocytes of pig. Sheng Wu Gong Cheng Xue Bao 2008; 24(8): 1361-6.
26. Dewulf EM, Ge Q, Bindels LB, et al. Evaluation of the relationship between GPR43 and adiposity in human. Nutr Metab (Lond) 2013; 10(1): 11.
27. Frost G, Cai Z, Raven M, Otway DT, Mushtaq R, Johnston JD. Effect of short chain fatty acids on the expression of free fatty acid receptor 2 (FFAR2), FFAR3 and early-stage adipogenesis. Nutr Diabetes 2014; 4: e128.
28. Lee T, Schwandner R, Swaminath G, et al. Identification and functional characterization of allosteric agonists for the G proteincoupled receptor FFA2. Mol Pharmacol 2008; 74(6): 1599-609.
29. Wang Y, Jiao X, Kayser F, et al. The first synthetic agonists of FFA2: Discovery and SAR of phenylacetamides as allosteric modulators. Bioorg Med Chem Lett 2010; 20(2): 493-8.
30. Raz I, Eldor R, Cernea S, Shafrir E. Diabetes: insulin resistance and derangements in lipid metabolism. Cure through intervention in fat transport and storage. Diabetes Metab Res Rev 2005; 21(1): 3-14.
31. Daniele G, Eldor R, Merovci A, et al. Chronic reduction of plasma free fatty acid improves mitochondrial function and whole-body insulin sensitivity in obese and type 2 diabetic individuals. Diabetes 2014; 63(8): 2812-20.
32. Tolhurst G, Heffron H, Lam YS, et al. Short-chain fatty acids stimulate glucagon-like peptide-1 secretion via the G-proteincoupled receptor FFAR2. Diabetes 2012; 61(2): 364-71.
33. Kimura I, Ozawa K, Inoue D, et al. The gut microbiota suppresses insulin-mediated fat accumulation via the short-chain fatty acid receptor GPR43. Nat Commun 2013; 4: 1829.
34. Bjursell M, Admyre T, Goransson M, et al. Improved glucose control and reduced body fat mass in free fatty acid receptor 2- deficient mice fed a high-fat diet. Am J Physiol Endocrinol Metab 2011; 300(1): E211-20.
35. Tang C, Ahmed K, Gille A, et al. Loss of FFA2 and FFA3 increases insulin secretion and improves glucose tolerance in type 2 diabetes. Nat Med 2015; 21(2): 173-7.
36. Karpe F, Fielding BA, Ilic V, Macdonald IA, Summers LK, Frayn KN. Impaired postprandial adipose tissue blood flow response is related to aspects of insulin sensitivity. Diabetes 2002; 51(8): 2467- 73.
37. Eriksson JW, Smith U, Waagstein F, Wysocki M, Jansson PA. Glucose turnover and adipose tissue lipolysis are insulin-resistant in healthy relatives of type 2 diabetes patients: is cellular insulin resistance a secondary phenomenon? Diabetes 1999; 48(8): 1572-8.
38. Federici M, Porzio O, Zucaro L, et al. Increased abundance of insulin/IGF-I hybrid receptors in adipose tissue from NIDDM patients. Mol Cell Endocrinol 1997; 135(1): 41-7.
39. Ahmad F, Considine RV, Bauer TL, Ohannesian JP, Marco CC, Goldstein BJ. Improved sensitivity to insulin in obese subjects following weight loss is accompanied by reduced protein-tyrosine phosphatases in adipose tissue. Metabolism 1997; 46(10): 1140-5.
40. Prager R, Wallace P, Olefsky JM. Hyperinsulinemia does not compensate for peripheral insulin resistance in obesity. Diabetes 1987 36(3): 327-34.
41. Olefsky JM, Kolterman OG. Mechanisms of insulin resistance in obesity and noninsulin-dependent (type II) diabetes. Am J Med 1981 70(1): 151-68.
42. Lonnroth P, Blohme G, Lager I, Tisell LE, Smith U. Insulin resistance in fat cells from insulin-treated type I diabetic individuals. Diabetes Care 1983; 6(6): 586-90.
43. Lager I, Lonnroth P, von Schenck H, Smith U. Reversal of insulin resistance in type I diabetes after treatment with continuous subcutaneous insulin infusion. Br Med J (Clin Res Ed) 1983; 287(6406): 1661-4.
44. Kolterman OG, Gray RS, Griffin J, et al. Receptor and postreceptor defects contribute to the insulin resistance in noninsulin-dependent diabetes mellitus. J Clin Invest 1981; 68(4): 957-69.
45. Ferrannini E. The insulin resistance syndrome. Curr Opin Nephrol Hypertens 1992; 1(2): 291-8.
46. Petersen KF, Dufour S, Morino K, Yoo PS, Cline GW, Shulman GI. Reversal of muscle insulin resistance by weight reduction in young, lean, insulin-resistant offspring of parents with type 2 diabetes. Proc Natl Acad Sci USA 2012; 109(21): 8236-40.
47. He M, Su H, Gao W, et al. Reversal of obesity and insulin resistance by a non-peptidic glucagon-like peptide-1 receptor agonist in dietinduced obese mice. PLoS One 2010; 5(12): e14205.
48. Lautt WW, Macedo MP, Sadri P, Legare DJ, Reid MA, Guarino MP. Pharmaceutical reversal of insulin resistance. Proc West Pharmacol Soc 2004; 47: 30-2.